Skip to main content
Journal of Analytical Science and Technology

Table 4 Assay results for the determination of SF and VP in pharmaceutical dosage forma using all the proposed methods (n = 5)

From: Eco-friendly analytical methods for the determination of compounds with disparate spectral overlapping: application to antiviral formulation of sofosbuvir and velpatasvir

 

SF

VP

2DD

ΔA

ΔD1

DC

Reference method (Rezk et al., 2019b)

NBD-Cl-UV

NBD-Cl-Flu

MBTH-UV

Reference method (Attia et al., 2018)

λ (nm)

254

232

245

D1 273/D1 299

D1 273/D1 355

260

436

λem/ex, 550/480

709

339

% Recovery

101.0

100.5

100.4

100.2

99.8

99.1

99.8

100.4

99.8

100.9

SD

1.165

0.82

1.463

0.84

1.16

0.95

0.92

0.66

1.44

0.78

t test(b)

1.13

2.08

2.17

2.14

1.83

N/A

1.86

0.36

1.83

N/A

F test(b)

2.15

1.07

2.36

1.11

2.81

N/A

5.87

1.08

1.02

N/A

  1. (a)Epclusa® tablets reported to contain 400 mg SF and 100 mg VP
  2. (b)Theoretical values of t and F for p = 0.05 are 2.31 and 6.39, respectively
Back to article page